Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical. We are particularly interested in speaking with those with interest in hematological, immunological, ophthalmological as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development, co-development partnerships, and out-licensing of novel cell conversions applicable to non-core markets.
Dr. Karin Schmitt, Chief Business Officer, Mogrify
BIO-Europe Digital comes at a time when global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward. Join the BIO-Europe Digital to schedule virtual partnering meetings during the week of October 26–29.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.